Fig. 4

Alpelisib improves and prevent capillary venous malformations in PIK3CA^Tie2-CreER mice. a Kaplan–Meier survival curves of PIK3CA^WT and PIK3CA^Tie2-CreER mice treated with either vehicle or preventive alpelisib (n = 12 per group). b Coronal whole-body T2-weighted magnetic resonance images (MRI) of PIK3CA^WT and PIK3CA^Tie2-CreER mice 6 weeks after Cre recombination treated with either vehicle, preventive or therapeutic alpelisib (n = 4–6 mice per group). Volumetric quantification of the vascular malformations. c Representative hematoxylin and eosin (H&E) staining of the skin of PIK3CA^WT and PIK3CA^Tie2-CreER mice treated with either vehicle, preventive or therapeutic alpelisib. Scale bar: 10 μm. d Representative P-AKT^Thr308 and P-S6RP immunostaining in the skin of PIK3CA^WTand PIK3CA^Tie2-CreER mice treated with either vehicle, preventive or therapeutic alpelisib. Scale bar: 10 μm. e Western blot and quantification of P-AKT^Ser473 and P-S6RP in skin of PIK3CA^WTand PIK3CA^Tie2-CreER mice treated with either vehicle, preventive or therapeutic alpelisib (n = 6–7 mice per group). f Complete blood count of PIK3CA^WTand PIK3CA^Tie2-CreER mice treated with either vehicle, preventive or therapeutic alpelisib (n = 5–10 mice). g Representative photography of PIK3CA^Tie2-CreER mice before and two weeks after alpelisib initiation. h Kaplan–Meier survival curves of PIK3CA^WT and PIK3CA^Tie2-CreER mice treated with either vehicle or therapeutic alpelisib (n = 12 per group)